You can now count the Australian government as a major supporter of regenerative medicine research. Prime Minister Kevin Rudd has unveiled a $250 million public/private fund to back new work in the field, taking a stake in early-stage labor that will take years--and years--to pay off.
Few people in the U.K.'s biotech industry have as much influence as Chris Evans. That influence was on full display this week after the high-flying investor took a personal, million-dollar stake in the regenerative medicine company ReNeuron, which is being refinanced and moved to Wales as part of a Welsh government effort to build a biotech hub in the region.
Scientists may have unlocked a way to therapeutically correct genetic defects by using a new technique that targets and repairs defective genes.
Score one for stem cell scientists in the hunt to regenerate human livers. A group from Yokohama City University in Japan has reported that lab-grown human liver "buds" were injected into mice and performed the detoxification functions.
Celgene has invested further in the cash-hungry regenerative medicine specialist Tengion, which tapped the biopharma powerhouse and other backers for a total of $33.6 million to support its two lead programs in early clinical development.
The U.K. could be lagging behind in regenerative medicine and missing out on opportunities to translate basic science to commercially viable treatments, a new report by Parliament's House of Lords found.
Roche may be jumping into the diagnostics M&A pool once again, a year after Illumina spurned its $6.8 billion offer. Reuters reports that the Swiss pharmaceutical company is joining a bidding war for Life Technologies.
Wright Medical, an orthopedic device maker, is now the proud new owner of regenerative medicine company BioMimetic Therapeutics. The $190 million-plus cash and stock acquisition deal closed at the end of February.
Stem cell-based therapeutics are a fast-growing area of early-stage biotech research, but they need better production methods to enable large-scale R&D.
Eyeing growth in the regenerative medicine field, Wright Medical Group is making a calculated gamble on BioMimetic Therapeutics ($BMTI), agreeing to acquire the company for $190 million up front and $190 million down the road depending on certain milestones.